# Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

> **NCT07382687** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 248 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Famitinib+SHR-A1811

## Key facts

- **NCT ID:** NCT07382687
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382687, "Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07382687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*